See more : Asti Corporation (6899.T) Income Statement Analysis – Financial Results
Complete financial analysis of Mirum Pharmaceuticals, Inc. (MIRM) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Mirum Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Tecnotree Oyj (0ONY.L) Income Statement Analysis – Financial Results
- Poly Medicure Limited (POLYMED.NS) Income Statement Analysis – Financial Results
- Copper Lake Resources Ltd. (CPL.V) Income Statement Analysis – Financial Results
- SSH Group Limited (SSH.AX) Income Statement Analysis – Financial Results
- Kohsai Co.,Ltd. (7878.T) Income Statement Analysis – Financial Results
Mirum Pharmaceuticals, Inc. (MIRM)
About Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 186.37M | 77.06M | 19.14M | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 47.04M | 12.37M | 1.90M | 623.00K | 324.00K | 0.00 |
| Gross Profit | 139.34M | 64.69M | 17.24M | -623.00K | -324.00K | 0.00 |
| Gross Profit Ratio | 74.76% | 83.94% | 90.06% | 0.00% | 0.00% | 0.00% |
| Research & Development | 102.61M | 106.84M | 131.43M | 81.61M | 42.99M | 2.33M |
| General & Administrative | 139.58M | 16.96M | 59.22M | 22.69M | 11.75M | 877.50K |
| Selling & Marketing | 6.30M | 72.11M | 9.20M | 0.00 | 0.00 | -292.50K |
| SG&A | 145.88M | 89.07M | 59.22M | 22.69M | 11.75M | 585.00K |
| Other Expenses | 0.00 | 365.00K | 107.42M | -192.00K | -21.00K | 0.00 |
| Operating Expenses | 248.49M | 195.91M | 190.65M | 104.30M | 54.74M | 2.92M |
| Cost & Expenses | 295.53M | 208.28M | 192.55M | 104.30M | 54.74M | 2.92M |
| Interest Income | 13.74M | 3.86M | 366.00K | 1.56M | 2.23M | 87.00K |
| Interest Expense | 15.11M | 15.98M | 17.59M | 335.00K | 0.00 | 0.00 |
| Depreciation & Amortization | 10.83M | 3.68M | 975.00K | 623.00K | 324.00K | 4.37M |
| EBITDA | -136.49M | -122.41M | -65.39M | -102.31M | -52.21M | -17.33M |
| EBITDA Ratio | -73.23% | -164.80% | -337.83% | 0.00% | 0.00% | 0.00% |
| Operating Income | -109.15M | -131.22M | -173.41M | -104.30M | -54.74M | -2.92M |
| Operating Income Ratio | -58.57% | -170.28% | -906.12% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -53.27M | -10.85M | 89.46M | 1.03M | 2.21M | -14.43M |
| Income Before Tax | -162.42M | -142.07M | -83.95M | -103.26M | -52.53M | -17.35M |
| Income Before Tax Ratio | -87.15% | -184.36% | -438.66% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 991.00K | -6.41M | 37.00K | 6.00K | 21.00K | -4.37M |
| Net Income | -163.42M | -135.67M | -83.99M | -103.27M | -52.55M | -17.35M |
| Net Income Ratio | -87.68% | -176.05% | -438.85% | 0.00% | 0.00% | 0.00% |
| EPS | -4.00 | -4.01 | -2.77 | -4.09 | -2.29 | -0.75 |
| EPS Diluted | -4.00 | -4.01 | -2.77 | -4.09 | -2.29 | -0.75 |
| Weighted Avg Shares Out | 40.89M | 33.84M | 30.32M | 25.25M | 22.99M | 22.99M |
| Weighted Avg Shares Out (Dil) | 40.89M | 33.84M | 30.32M | 25.25M | 22.99M | 22.99M |
Mirum Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will report first quarter 2024 financial results on May 8, 2024. Mirum will also host a conference call to discuss the first quarter 2024 financial results and recent...
Mirum Pharmaceuticals, Inc. (MIRM) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Mirum Pharmaceuticals (MIRM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mirum Pharmaceuticals: After Phase 2 Miss, An iBAT Inhibitor On Deck To Drive Value
The FDA approved Mirum Pharmaceuticals, Inc.'s Limvarli for treatment of cholestatic pruritus in patients with Progressive Familial Intrahepatic Cholestasis; Potential for further label expansion in younger patients possible due to positive MARCH study. Interim results from VANTAGE study using Volixibat...
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
Mirum Pharmaceuticals' LIVMARLI (maralixibat oral solution) Receives Positive Reimbursement Recommendation by Canada's CADTH for Patients with Cholestatic Pruritus in Alagille Syndrome
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #alagillesyndrome--Mirum's LIVMARLI Receives Positive Reimbursement Recommendation by Canada's CADTH for Patients with Cholestatic Pruritus in Alagille Syndrome.
Mirum's (MIRM) Livmarli Receives FDA Nod for Expanded Use
Mirum's (MIRM) Livmarli gets FDA approval for label expansion to include the treatment of cholestatic pruritus in patients aged five years and older with PFIC.
Mirum Pharmaceuticals' LIVMARLI Receives FDA Approval for Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #pfic--Mirum's LIVMARLI Receives FDA Approval for Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis.
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
Mirum Pharmaceuticals: Advancing On Several Key Fronts
Mirum Pharmaceuticals delivered solid Q4 results last week, with projected sales growth of around 70% for fiscal year 2024. The company's primary growth driver is Livmarli, an oral solution approved for the treatment of cholestatic pruritus for Alagille syndrome patients....
Mirum's (MIRM) Q4 Earnings Lag Estimates, Revenues Beat
Mirum's (MIRM) earnings fall shy of estimates in the fourth quarter of 2023 while revenues beat the same.
Source: https://incomestatements.info
Category: Stock Reports